about
Activation of Toll‐like receptor 9 inhibits lipopolysaccharide‐induced receptor activator of nuclear factor kappa‐ B ligand expression in rat B lymphocytes.Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulatorsThe use of herbal and over-the-counter dietary supplements for the prevention of prostate cancer.Infection with Toxoplasma gondii results in dysregulation of the host cell cycle.Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer.A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.Silibinin impairs constitutively active TGFalpha-EGFR autocrine loop in advanced human prostate carcinoma cells.Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells.UV Induces p21 rapid turnover independently of ubiquitin and Skp2.Unique natural antioxidants (NAOs) and derived purified components inhibit cell cycle progression by downregulation of ppRb and E2F in human PC3 prostate cancer cells.Retinoblastoma gene-independent G1 phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor, and histone deacetylase inhibitor.Cell-cycle regulators cdk2ap1 and bicalutamide suppress malignant biological interactions between prostate cancer and bone cells.Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators.
P2860
Q33570032-7660567A-9E70-4C1B-AB0A-1FBC56E25E02Q34002839-B70B4740-4C6E-46C2-8B24-5C3E9209AEB5Q34627739-8B1BC1D2-262F-4F39-A10B-30DD8BEB530FQ36450799-84E55DA9-15E2-408B-8B68-3574CAC90AA3Q37109789-3E864699-03F5-4D39-9F7A-71A6ECED22C0Q37591742-62FB086A-5D4D-4749-8E3A-7B4AE727FC4AQ38723294-E5607517-1339-4161-A427-79F8FFB851BAQ38895320-2861F6B0-A556-4ACC-961F-635F86020EC2Q40016059-31165074-9CA6-427D-A76F-684840CBD8CCQ40182115-74DD94E2-D003-469F-AD9D-4DF63991EF80Q40262460-06194C26-0098-413F-99BA-87673C52E636Q40522691-B3F5661F-4C63-4871-A590-57E474DDB35BQ53146759-52FF98A3-1867-495E-80C7-2B77D4C1FA47Q53302883-33993D68-6A8C-42D8-91D3-463AF38D6B89Q55332470-90B7DB6C-D1A4-4200-A950-57E00352B7C2
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
CDK inhibitors: cell cycle arrest versus apoptosis.
@ast
CDK inhibitors: cell cycle arrest versus apoptosis.
@en
CDK inhibitors: cell cycle arrest versus apoptosis.
@nl
type
label
CDK inhibitors: cell cycle arrest versus apoptosis.
@ast
CDK inhibitors: cell cycle arrest versus apoptosis.
@en
CDK inhibitors: cell cycle arrest versus apoptosis.
@nl
prefLabel
CDK inhibitors: cell cycle arrest versus apoptosis.
@ast
CDK inhibitors: cell cycle arrest versus apoptosis.
@en
CDK inhibitors: cell cycle arrest versus apoptosis.
@nl
P356
P1433
P1476
CDK inhibitors: cell cycle arrest versus apoptosis.
@en
P2093
Gary K Schwartz
P304
P356
10.4161/CC.1.2.115
P577
2002-03-01T00:00:00Z